Jean-Charles Wirth, CEO of Merck Life Science, noted in a recent interview that the company is investing 300 million euros ($338 million) in a new Daejeon manufacturing center—its largest life science investment in Asia-Pacific to date—to tap into Asia’s rapidly expanding biopharmaceutical market and strengthen its "in-region, for-region" supply chain strategy.
During the interview, Wirth highlighted Korea’s exceptional scientific talent pool and strategic proximity to key customers as primary drivers for selecting Daejeon. He also outlined plans to foster the broader domestic bio ecosystem by supporting both major players and emerging biotech startups through initiatives like the Advance Biotech Grant Program Korea.
For more details, please visit the link.